Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of Stakel (padeliporfin) VTP Therapy in Neovascular AMD
2009-017435-18Phase 2Active
- Sponsor
- Steba Biotech
- Start
- Dec 2009
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of padeliporfin in exudative macular degeneration and Subretinal neovascularization, sponsored by Steba Biotech. Primary endpoint: Primary safety endpoint. Started Dec 2009; status: active.
02
Drugs
padeliporfin
03
Conditions
exudative macular degenerationSubretinal neovascularization
Beyond the preview
Go deeper on 2009-017435-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017435-18.